Finanzen von Dianthus Therapeutics Inc (DNTH)DNTHDianthus Therapeutics Inc

Evaluating the bottom line, Dianthus Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8079.11%, while the net margin is -6598.55%. These profitability ratios, combined with a Return on Equity (ROE) of -26.07%, provide a clear picture of how effectively DNTH converts its operational activities into shareholder value.

In the context of the broader market, DNTH competes directly with industry leaders such as EWTX and ADPT. With a market capitalization of $4.17B, it holds a significant position in the sector. When comparing efficiency, DNTH's gross margin of 100.00% stands against EWTX's N/A and ADPT's 71.23%. Such benchmarking helps identify whether Dianthus Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Dianthus has shown a gross margin of 100% consistently, but it has also reported significant net income losses, such as -$50,215,000 for Q2 2026. The current ratio is strong at 26.10, indicating good short-term financial health.